The Journal of Allergy and Clinical Immunology: In Practice
Practice ParameterContact Dermatitis: A Practice Parameter–Update 2015
Section snippets
Preface
The Practice Parameter on Contact Dermatitis (CD) was last updated in 2006, and focused primarily on the basics of CD and patch testing for the allergist. In the ensuing years, there has been considerable interest by the allergist in allergic skin diseases due to increasing numbers of referrals for CD. With the ease of application, the use of the preloaded commercially available T.R.U.E. Test patch testing method has increased among allergists, as has the use of patch testing with individually
Glossary
“Angry back” syndrome or “excited skin” syndrome: defined as false-positive patch test (PT) reactions usually adjacent to large true-positive reactions that induce contiguous skin inflammation and irritability.
Ectopic allergic contact dermatitis: contact allergy lesions manifested in locations distant from or indirectly in contact with the original skin sites directly exposed to allergens due to inadvertent transfer by the patient (eg, transfer of sensitizers in nail polish to the eyelids) or
Compilation of Summary Statements
Summary Statement 1: Consider ACD in the differential diagnosis of patients with chronic eczematous or noneczematous dermatitis. [Strength of Recommendation: Strong; C Evidence]
Summary Statement 2: In patients suspected of ACD, patch testing is the gold standard to confirm the diagnosis. [Strength of Recommendation: Strong; C Evidence]
Summary Statement 3: In addition to personal products used by a patient suspected of ACD, review the home and workplace for other sources of contact allergens.
Executive Summary
Contact dermatitis may be suspected on the basis of the clinical appearance of the cutaneous lesions, the distribution of the dermatitis, and the absence of other etiologies. Acute CD is characterized by erythematous papules, vesicles, and crusted lesions. There are other dermatological conditions that may resemble the clinical and/or histological appearance of CD, and these should be considered in the differential diagnosis. The suspicion of ACD is the first step in making the diagnosis. Patch
Clinical evaluation
Summary Statement 1: Consider ACD in the differential diagnosis of patients with chronic eczematous or noneczematous dermatitis. [Strength of Recommendation: Strong; C Evidence]
Contact dermatitis may be suspected on the basis of the clinical appearance of the lesions, the distribution of the dermatitis, and the absence of other etiologies or lack of associated systemic manifestations. Acute CD is characterized by erythematous papules, vesicles, and crusted lesions. Recurrent or persistent
References (282)
- et al.
North American Contact Dermatitis Group patch test results for the detection of delayed-type hypersensitivity to topical allergens
J Am Acad Dermatol
(1998) - et al.
The value of patch testing patients with a scattered generalized distribution of dermatitis: retrospective cross-sectional analyses of North American Contact Dermatitis Group data, 2001 to 2004
J Am Acad Dermatol
(2008) - et al.
Impact of patch testing on dermatology-specific quality of life in patients with allergic contact dermatitis
Am J Contact Dermat
(1997) - et al.
Allergic contact dermatitis to detergents: a multicenter study to assess prevalence
J Am Acad Dermatol
(2002) - et al.
Abnormal epidermal barrier in the pathogenesis of contact dermatitis
Clin Dermatol
(2012) - et al.
Current dilemmas and controversies in allergic contact dermatitis to ophthalmic medications
Clin Dermatol
(2011) - et al.
Periorbital contact sensitization
Am J Ophthalmol
(2010) - et al.
Contact allergy in oral disease
J Am Acad Dermatol
(2007) - et al.
Allergic patch test reactions associated with cosmetics: retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2004
J Am Acad Dermatol
(2009) Contact allergens for armpits—allergenic fragrances specified on deodorants
Int J Hyg Environ Health
(2012)
Allergic contact dermatitis from a natural deodorant: a report of 4 cases associated with lichen acid mix allergy
J Am Acad Dermatol
Deodorants: an experimental provocation study with cinnamic aldehyde
J Am Acad Dermatol
Allergic contact dermatitis in response to budesonide reactivated by inhalation of the allergen
J Am Acad Dermatol
Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis
J Am Acad Dermatol
Measurement of ultraviolet radiation-induced suppression of recall contact and delayed-type hypersensitivity in humans
Methods
Broad-spectrum sunscreens provide greater protection against ultraviolet-radiation-induced suppression of contact hypersensitivity to a recall antigen in humans
J Invest Dermatol
Delayed patch test reading after 5 days: the Mayo Clinic experience
J Am Acad Dermatol
Contact dermatitis mimickers: a tertiary care center's experience
J Cutan Med Surg
Clues to an accurate diagnosis of contact dermatitis
Dermatol Ther
Validity of self-reported nickel allergy
Contact Dermatitis
North American Contact Dermatitis Group patch-test results, 1998 to 2000
Am J Contact Dermat
North American Contact Dermatitis Group patch-test results, 2001-2002 study period
Dermatitis
The British standard series of contact dermatitis allergens: validation in clinical practice and value for clinical governance
Br J Dermatol
Role of contact allergens in pompholyx
J Dermatol
Patch testing in prurigo nodularis
Contact Dermatitis
Allergic contact dermatitis in children: should pattern of dermatitis determine referral? A retrospective study of 500 children tested between 1995 and 2004 in one U.K. centre
Br J Dermatol
Comparison of personal history with patch test results in metal allergy
J Dermatol
Patch testing of 490 patients in Hong Kong
Contact Dermatitis
Allergic skin disease: investigation of both immediate- and delayed-type hypersensitivity is essential
Clin Exp Allergy
Sensitization induced by patch testing
Br J Dermatol
Active sensitization to beryllium by diagnostic patch tests
J Dermatol
Epicutaneous patch testing
Eur J Dermatol
Occupational risk factors for hand dermatitis among professional cleaners in Spain
Contact Dermatitis
Allergic contact dermatitis among construction workers detected in a clinic that did not specialize in occupational dermatitis
An Bras Dermatol
Hand dermatitis among university hospital nursing staff with or without atopic eczema: assessment of risk factors
Contact Dermatitis
Are material safety data sheets (MSDS) useful in the diagnosis and management of occupational contact dermatitis?
Contact Dermatitis
Augmentation of skin response by exposure to a combination of allergens and irritants—a review
Contact Dermatitis
North American Contact Dermatitis Group Patch Test Results: 2009 to 2010
Dermatitis
Patch testing in children with hand eczema. A 5-year multicentre study in Spain
Contact Dermatitis
Periorbital dermatitis—a recalcitrant disease: causes and differential diagnoses
Br J Dermatol
Compositae dermatitis
Aust J Dermatol
Periocular dermatitis: a report of 401 patients
J Eur Acad Dermatol Venereol
Eyelid dermatitis: a report of 215 patients
Contact Dermatitis
Patch-testing North American lip dermatitis patients: data from the North American Contact Dermatitis Group, 2001 to 2004
Dermatitis
Epidemiology of eczematous cheilitis at a tertiary dermatological referral centre in Singapore
Contact Dermatitis
Multicentre study of allergic contact cheilitis from toothpastes
Contact Dermatitis
Acute allergic contact dermatitis of the lips from peppermint oil in a lip balm
Dermatitis
Dental allergic contact dermatitis: an interesting case series and review of the literature
Dermatitis
20 Years of standard patch testing in an eczema population with focus on patients with multiple contact allergies
Contact Dermatitis
The prevalence of allergic contact sensitization in a general population in Tromso, Norway
Int J Circumpolar Health
Cited by (107)
Drug patch testing for severe cutaneous adverse reactions: Not in the United States?
2023, Annals of Allergy, Asthma and ImmunologySystemic contact dermatitis to peanut ingestion
2023, Annals of Allergy, Asthma and ImmunologyManagement of Allergic Skin Disorders in Pregnancy
2023, Immunology and Allergy Clinics of North AmericaDrug allergy: A 2022 practice parameter update
2022, Journal of Allergy and Clinical ImmunologyPatch testing results in adult patients with dermatitis during the coronavirus disease 2019 pandemic
2022, Annals of Allergy, Asthma and Immunology
See Appendix A for members of the Joint Task Force Contact Dermatitis Parameter Workgroup, reviewers of this Practice Parameter, and members of the Joint Task Force on Practice Parameters.
Disclosure of potential conflict of interest: L. Fonacier has received research and educational grants (made to Winthrop University Hospital) from Genentech, Merck, and Baxter; is in the Speaker's Bureau/Honoraria of Baxter; and is on the Board of Directors, Joint Council of Allergy, Asthma and Immunology (JCAAI) 2012-2015. D. Bernstein is the consultant in Merck, Genentech, Proctor and Gamble, Sanofi, and TEVA; and has received research grants from Amgen, GlaxoSmithKline, Greer, Johnson & Johnson, Merck, Teva, Pfizer, Genentech, Array, Cephalon, Novartis, Boeringer Ingelheim, and Medimmune. The rest of the authors declare that they have no relevant conflicts of interest.
The Joint Task Force recognizes that experts in a field are likely to have interests that could come into conflict with the development of a completely unbiased and objective practice parameter. To take advantage of that expertise, a process has been developed to prevent potential conflicts from influencing the final document in a negative way.
At the workgroup level, members who have a potential conflict of interest either do not participate in discussions concerning topics related to the potential conflict or if they do write a section on that topic, the workgroup completely rewrites it without their involvement to remove potential bias. In addition, the entire document is then reviewed by the Joint Task Force and any apparent bias is removed at that level. Finally, the practice parameter is sent for review both by invited reviewers and by anyone with an interest in the topic by posting the document on the web sites of the ACAAI and the AAAAI.
Corresponding author: Joint Task Force on Practice Parameters, 59 N Brockway St, #304, Palatine, IL 60067. E-mail: [email protected].